Goldman Sachs Starts Surface Oncology (SURF) at Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/14/2026
- Nasdaq futures slide as AI warnings rattle markets; Nvidia, other chip stocks retreat
- Global AI stocks fall as industry chiefs call for slowing development
- Oil prices continue surge, rising 3% amid Saudi pipeline outage after attack
- BofA sees just 2% upside for the S&P 500 over the next 12 months
- Wall Street's new pair trade: Long software, short chips
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Evercore ISI Starts Surface Oncology (SURF) at Outperform
May 14, 2018 6:04 AM EDTEvercore ISI initiates coverage on Surface Oncology (NASDAQ: SURF) with a Outperform rating and a price target of $26.00.
Analyst Josh Schimmer said they believe SURF's approach of targeting the innate immune system as well is differentiated, and the company is developing a portfolio of... More
Cowen Starts Surface Oncology (SURF) at Outperform
May 14, 2018 5:38 AM EDTCowen initiates coverage on Surface Oncology (NASDAQ: SURF) with a Outperform rating.
Analyst Boris Peaker comments "Surface is developing several drugs against novel IO targets. Given the early stage nature of these targets, we believe that positive developments internally as well as... More
